Back to News
Market Impact: 0.2
HC Wainwright & Co. Initiates Coverage of Eikon Therapeutics with Buy Rating
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
HC Wainwright & Co. initiated coverage of Eikon Therapeutics with a Buy recommendation on October 16, 2026. Eikon closed at $7.54 on October 15; the article provides no subsequent share-price reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
EIKN0.55
More News
- Apple’s $1,999 iPhone Duo puts the company's status-symbol power to the test
- Yields continue to rattle investors. These sectors are most at risk if rates stay elevated
- We're downgrading this retail stock after a big comeback. Plus, AI names slide again
- Kimberly-Clark is having its best week in four years. Here's what is propelling shares higher
- The drumbeat to buy battered shares of CoreWeave is growing louder on Wall Street
- Why is Snowflake stock tumbling today?